INSYS Therapeutics, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'INSYS Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the INSYS Therapeutics, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by INSYS Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of INSYS Therapeutics, Inc. - The report provides overview of INSYS Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses INSYS Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features INSYS Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate INSYS Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for INSYS Therapeutics, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding INSYS Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Content 2 List of Tables 4 List of Figures 4 INSYS Therapeutics, Inc. Snapshot 5 INSYS Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 INSYS Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 INSYS Therapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 INSYS Therapeutics, Inc. - Pipeline Products Glance 12 INSYS Therapeutics, Inc. - Late Stage Pipeline Products 12 Pre-Registration Products/Combination Treatment Modalities 12 Phase III Products/Combination Treatment Modalities 13 INSYS Therapeutics, Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 INSYS Therapeutics, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 INSYS Therapeutics, Inc. - Drug Profiles 17 dronabinol 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 buprenorphine hydrochloride 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Cannabidiol 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 (buprenorphine hydrochloride + naloxone hydrochloride) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 naloxone hydrochloride 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ondansetron hydrochloride 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 paclitaxel 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 cetirizine hydrochloride + cromolyn sodium 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 diclofenac sodium 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ketorolac tromethamine 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 sildenafil citrate 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 INSYS Therapeutics, Inc. - Pipeline Analysis 30 INSYS Therapeutics, Inc. - Pipeline Products by Target 30 INSYS Therapeutics, Inc. - Pipeline Products by Route of Administration 32 INSYS Therapeutics, Inc. - Pipeline Products by Molecule Type 33 INSYS Therapeutics, Inc. - Pipeline Products by Mechanism of Action 34 INSYS Therapeutics, Inc. - Recent Pipeline Updates 35 INSYS Therapeutics, Inc. - Dormant Projects 38 INSYS Therapeutics, Inc. - Discontinued Pipeline Products 39 Discontinued Pipeline Product Profiles 39 Monoclonal Antibody Conjugate to Target Mesothelin for Oncology 39 INSYS Therapeutics, Inc. - Company Statement 40 INSYS Therapeutics, Inc. - Locations And Subsidiaries 43 Head Office 43 Other Locations & Subsidiaries 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
INSYS Therapeutics, Inc., Key Information 5 INSYS Therapeutics, Inc., Key Facts 5 INSYS Therapeutics, Inc. - Pipeline by Indication, 2016 7 INSYS Therapeutics, Inc. - Pipeline by Stage of Development, 2016 9 INSYS Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 10 INSYS Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016 11 INSYS Therapeutics, Inc. - Pre-Registration, 2016 12 INSYS Therapeutics, Inc. - Phase III, 2016 13 INSYS Therapeutics, Inc. - Phase II, 2016 14 INSYS Therapeutics, Inc. - Phase I, 2016 15 INSYS Therapeutics, Inc. - Preclinical, 2016 16 INSYS Therapeutics, Inc. - Pipeline by Target, 2016 30 INSYS Therapeutics, Inc. - Pipeline by Route of Administration, 2016 32 INSYS Therapeutics, Inc. - Pipeline by Molecule Type, 2016 33 INSYS Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 34 INSYS Therapeutics, Inc. - Recent Pipeline Updates, 2016 35 INSYS Therapeutics, Inc. - Dormant Developmental Projects,2016 38 INSYS Therapeutics, Inc. - Discontinued Pipeline Products, 2016 39 INSYS Therapeutics, Inc., Other Locations 43 INSYS Therapeutics, Inc., Subsidiaries 43
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.